Imvotamab is a bispecific T cell engaging IgM antibody targeting CD20 and CD3 proteins. We believe that imvotamab, with its 10 binding units for CD20, may successfully bind to CD20 expressing B cells with more power (avidity) compared to an IgG bispecific antibody with only one or two binding units for CD20.
Imvotamab may offer important advantages over existing B cell therapies. Preclinical studies show that imvotamab penetrates and depletes CD20 expressing cells deep within various tissues, including bone marrow, spleen, and lymph nodes. Additionally, in vitro studies show that imvotamab is significantly more effective than rituximab in depleting low CD20 expressing cells. Collectively, these data suggest that imvotamab may offer the potential for deeper depletion than currently approved antibody therapies.